サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654223

光線性角化症治療の市場規模、シェア、動向分析レポート：治療法別、薬剤クラス別、最終用途別、地域別、セグメント予測、2025年～2030年

Actinic Keratosis Treatment Market Size, Share & Trends Analysis Report By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class (NSAIDs), By End use, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
光線性角化症治療の市場規模、シェア、動向分析レポート：治療法別、薬剤クラス別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年01月03日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

光線性角化症治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の光線性角化症治療市場規模は、2025年から2030年にかけてCAGR 4.1％を記録し、2030年までに89億3,000万米ドルに達する見込みです。

同市場は、光線性角化症治療薬の幅広い入手可能性、疾患に対する意識の高まり、AK治療の増加などの要因により、成長機会を迎えると予想されます。さらに、光線性角化症の有病率の増加や世界の老人人口の増加が、予測期間中の市場成長を促進すると予想されます。

浸潤性扁平上皮がんは、AKから悪性化（iSCC）すると開発される可能性があります。iSCCの潜在的な原因はいくつかありますが、AKは最も頻度の高い原因の1つです。さらに、基底細胞がんや非黒色腫皮膚がんもAKから発生する可能性があります。その結果、販売チャネルを問わずAK製品に対する需要は、合併症の予防戦略として、光線性角化症の早期診断と治療が原動力となっています。

さらに、将来のパイプライン医薬品と併用療法の増加が市場促進要因となっています。例えば、Almirall, S.A.は、研究開発第III相段階にあるKlisyri（適応拡大）を有しています。さらに、革新的な医薬品が受け入れられ商品化されるようになったことも、市場成長を促進する要因のひとつと予測されます。さらに、研究開発活動の活発化により、光線性角化症の治療に使用される新規薬剤の承認が加速されると予想されるため、予測期間中の成長が促進されます。

主要企業は、世界中で市場シェアを拡大するために、製品の発売、提携、拡大戦略などの戦略的イニシアチブを採用しています。例えば、2022年6月、BIOFRONTERA AGは、スイスに拠点を置くLouis Widmer SAが、Ameluzによる体幹、四肢、頸部の光線性角化症の管理に関する販売承認の延長を受けたと発表しました。さらに、BIOFRONTERA AGは2020年7月、ノルウェー、フィンランド、アイスランドにおけるBF-RhodoLEDおよびAmeluzの販売に関する契約をGalenica ABと締結したと発表しました。

光線性角化症治療市場レポートハイライト：

  • 光線性角化症の管理における凍結療法手術の採用が増加しているため、2024年には手術が63.8%の最大売上シェアを占めました。
  • ヌクレオシド代謝阻害剤は2024年に最大の収益シェアを占め、予測期間中もその優位性を維持すると予測されます。
  • アジア太平洋地域は、AKの有病率の高さ、急速に発展するヘルスケアインフラ、アジア太平洋諸国による医療費の増加などの要因により、予測期間中にCAGR 5.4%と最も速い速度で成長すると予想されます。
  • 北米は、光線性角化症に対する人々の意識の高まり、強固な治療オプションの利用可能性、ヘルスケアインフラの改善などにより、2024年に40.5%の最大の売上シェアを獲得し、市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 日光角化症治療市場の変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
    • 市場ドライバー分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析

第4章 日光角化症治療市場：治療法のビジネス分析

  • 治療法市場シェア、2024年と2030年
  • 治療法セグメントダッシュボード
  • 市場規模と予測および動向分析、治療法別、2018～2030年
  • 局所
  • 手術
  • 光線力学療法

第5章 日光角化症治療市場：薬物クラスのビジネス分析

  • 薬物クラス市場シェア、2024年および2030年
  • 薬物クラスセグメントダッシュボード
  • 市場規模と予測および動向分析、薬剤クラス別、2018～2030年
  • ヌクレオシド代謝阻害剤
  • NSAIDs
  • 免疫反応調節剤
  • 光増強剤
  • その他

第6章 日光角化症治療市場：最終用途のビジネス分析

  • 最終用途市場シェア、2024年および2030年
  • 最終用途セグメントダッシュボード
  • 市場規模と予測および動向分析、最終用途別、2018～2030年
  • 病院
  • 個人クリニック
  • ホームケア
  • その他

第7章 日光角化症治療市場：地域の推定・動向分析

  • 地域の市場シェア分析、2024年および2030年
  • 地域の市場ダッシュボード
  • 市場規模と予測動向分析、2018年から2030年：
  • 北米
    • 国別
    • 米国
    • カナダ
  • 欧州
    • 国別
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
  • ラテンアメリカ
    • 国別
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 国別
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第8章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Almirall, SA
    • LEO Pharma A/S
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • Galderma
    • Ortho Dermatologics（Bausch Health Companies Inc.）
    • BIOFRONTERA Inc
    • Hill Dermaceuticals, Inc
    • 3M
    • Alma Lasers
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global actinic keratosis treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 5 Global actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 Global actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 7 North America actinic keratosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 9 North America actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 North America actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 11 U.S. actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 12 U.S. actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 U.S. actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 14 Canada actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 15 Canada actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 16 Canada actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 17 Europe actinic keratosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 18 Europe actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 19 Europe actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 20 Europe actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 21 UK actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 22 UK actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 UK actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Germany actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 25 Germany actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 Germany actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 27 France actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 28 France actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 France actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Italy actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 31 Italy actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 Italy actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Spain actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 34 Spain actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 35 Spain actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific actinic keratosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 37 Asia Pacific actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Japan actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 41 Japan actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Japan actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 43 China actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 44 China actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 45 China actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 46 India actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 47 India actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 48 India actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 49 South Korea actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 50 South Korea actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 South Korea actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Australia actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 53 Australia actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 Australia actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 55 Latin America actinic keratosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 56 Latin America actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 57 Latin America actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 Latin America actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 59 Brazil actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 60 Brazil actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 61 Brazil actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Mexico actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 63 Mexico actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 Mexico actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Argentina actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 66 Argentina actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 67 Argentina actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 68 Middle East & Africa actinic keratosis treatment market, by country, 2018 - 2030 (USD Million)
  • Table 69 Middle East & Africa actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 70 Middle East & Africa actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 71 Middle East & Africa actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 72 South Africa actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 73 South Africa actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 74 South Africa actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 75 Saudi Arabia actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 76 Saudi Arabia actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 77 Saudi Arabia actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 78 UAE actinic keratosis treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 79 UAE actinic keratosis treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 80 UAE actinic keratosis treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Actinic keratosis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapy outlook (USD Million)
  • Fig. 10 Drug class outlook (USD Million)
  • Fig. 11 End use outlook (USD Million)
  • Fig. 12 Competitive landscape
  • Fig. 13 Actinic keratosis treatment market dynamics
  • Fig. 14 Actinic keratosis treatment market: Porter's five forces analysis
  • Fig. 15 Actinic keratosis treatment market: PESTLE analysis
  • Fig. 16 Actinic keratosis treatment market: Therapy segment dashboard
  • Fig. 17 Actinic keratosis treatment market: Therapy market share analysis, 2024 & 2030
  • Fig. 18 Topical market, 2018 - 2030 (USD Million)
  • Fig. 19 Surgery market, 2018 - 2030 (USD Million)
  • Fig. 20 Photodynamic therapy market, 2018 - 2030 (USD Million)
  • Fig. 21 Actinic keratosis treatment market: Drug class segment dashboard
  • Fig. 22 Actinic keratosis treatment market: Drug class market share analysis, 2024 & 2030
  • Fig. 23 Nucleoside metabolic inhibitor market, 2018 - 2030 (USD Million)
  • Fig. 24 NSAIDs market, 2018 - 2030 (USD Million)
  • Fig. 25 Immune response modifiers market, 2018 - 2030 (USD Million)
  • Fig. 26 Photoenhancers market, 2018 - 2030 (USD Million)
  • Fig. 27 Others market, 2018 - 2030 (USD Million)
  • Fig. 28 Actinic keratosis treatment market: End use segment dashboard
  • Fig. 29 Actinic keratosis treatment market: End use market share analysis, 2024 & 2030
  • Fig. 30 Hospitals market, 2018 - 2030 (USD Million)
  • Fig. 31 Private clinics market, 2018 - 2030 (USD Million)
  • Fig. 32 Homecare market, 2018 - 2030 (USD Million)
  • Fig. 33 Others market, 2018 - 2030 (USD Million)
  • Fig. 34 Actinic keratosis treatment market revenue, by region
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. country dynamics
  • Fig. 38 U.S. actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Europe actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 UK country dynamics
  • Fig. 43 UK actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Germany country dynamics
  • Fig. 45 Germany actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 France country dynamics
  • Fig. 47 France actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Italy country dynamics
  • Fig. 49 Italy actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain country dynamics
  • Fig. 51 Spain actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Japan country dynamics
  • Fig. 54 Japan actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 China country dynamics
  • Fig. 56 China actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 Latin America actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 66 Mexico country dynamics
  • Fig. 67 Mexico actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 MEA actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE actinic keratosis treatment market, 2018 - 2030 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework
目次
Product Code: GVR-2-68038-940-1

Actinic Keratosis Treatment Market Growth & Trends:

The global actinic keratosis treatment market size is expected to reach USD 8.93 billion by 2030, registering a CAGR of 4.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness growth opportunities owing to factors such as the wide availability of actinic keratosis therapeutics, rising awareness about the disease, and the rise in AK treatment. Moreover, the increasing prevalence of actinic keratosis and the rising geriatric population across the globe are expected to fuel the market growth during the forecast period.

Invasive squamous cell carcinoma may develop from AK when it becomes malignant (iSCC). Despite the fact that there are a number of potential causes for iSCC, AK is one of the most frequent ones. Additionally, basal cell carcinoma and non-melanoma skin cancer could result from AK. As a result, the demand for AK products across sales channels is being driven by the early diagnosis and treatment of actinic keratosis as a preventive strategy for comorbidities.

In addition, future pipeline medications and the increased use of combination therapy are key market drivers. For instance, Almirall, S.A. has Klisyri (extended label) in phase III of R&D. Furthermore, a rise in the acceptance and commercialization of innovative drugs is another factor that is predicted to fuel market growth. Moreover, increased R&D activities are expected to accelerate the approval of novel drugs used in the treatment of actinic keratosis, hence, propelling the growth over the forecast period.

Key players are adopting strategic initiatives such as product launches, partnerships, and expansion strategies to increase their market share across the globe. For instance, in June 2022, BIOFRONTERA AG announced that its license and marketing authorization holder Louis Widmer SA based in Switzerland has received an extension of its marketing authorization for the management of actinic keratosis in the trunk, extremities, and neck with Ameluz. Moreover, in July 2020, BIOFRONTERA AG announced that it has signed an agreement with Galenica AB for the marketing of BF-RhodoLED and Ameluz in Norway, Finland, and Iceland.

Actinic Keratosis Treatment Market Report Highlights:

  • Surgery held the largest revenue share of 63.8% in 2024 owing to the rising adoption of cryotherapy surgery in the management of actinic keratosis
  • Nucleoside metabolic inhibitors held the largest revenue share in 2024 and is expected to retain its dominance over the forecast period
  • Asia Pacific is expected to grow at the fastest CAGR of 5.4% during the forecast period due to factors such as the high prevalence of AK, rapidly evolving healthcare infrastructure, and rising healthcare expenditures by Asia Pacific countries
  • North America dominated the market with the largest revenue share of 40.5% in 2024 due to the rising awareness among people about actinic keratosis, availability of robust treatment options, and improvements in healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. Drug Class
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Actinic Keratosis Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Actinic Keratosis Treatment Market: Therapy Business Analysis

  • 4.1. Therapy Market Share, 2024 & 2030
  • 4.2. Therapy Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 4.4. Topical
    • 4.4.1. Topical Market, 2018 - 2030 (USD Million)
  • 4.5. Surgery
    • 4.5.1. Surgery Market, 2018 - 2030 (USD Million)
  • 4.6. Photodynamic Therapy
    • 4.6.1. Photodynamic Therapy Market, 2018 - 2030 (USD Million)

Chapter 5. Actinic Keratosis Treatment Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Nucleoside Metabolic Inhibitor
    • 5.4.1. Nucleoside Metabolic Inhibitor Market, 2018 - 2030 (USD Million)
  • 5.5. NSAIDs
    • 5.5.1. NSAIDs Market, 2018 - 2030 (USD Million)
  • 5.6. Immune Response Modifiers
    • 5.6.1. Immune Response Modifiers Market, 2018 - 2030 (USD Million)
  • 5.7. Photoenhancers
    • 5.7.1. Photoenhancers Market, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Actinic Keratosis Treatment Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 6.5. Private Clinics
    • 6.5.1. Private Clinics Market, 2018 - 2030 (USD Million)
  • 6.6. Homecare
    • 6.6.1. Homecare Market, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Actinic Keratosis Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Actinic Keratosis Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Actinic Keratosis Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Actinic Keratosis Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Mexico
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Mexico Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.4. Argentina
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Regulatory Framework
      • 7.7.4.3. Competitive Insights
      • 7.7.4.4. Argentina Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Actinic Keratosis Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Actinic Keratosis Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Almirall, S.A
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. LEO Pharma A/S
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Sun Pharmaceutical Industries Ltd.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Novartis AG
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Galderma
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Ortho Dermatologics (Bausch Health Companies Inc.)
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. BIOFRONTERA Inc
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Hill Dermaceuticals, Inc
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. 3M
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Alma Lasers
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives